PMID- 22475146
OWN - NLM
STAT- MEDLINE
DCOM- 20121129
LR  - 20181023
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 20
IP  - 3
DP  - 2012 Mar
TI  - [Histone deacetylase inhibitor MS-275 treatment alters immune molecule content 
      and categories in hepatocarcinoma exosomes].
PG  - 231-5
LID - cma.j.issn.1007-3418.2012.03 [pii]
LID - 10.3760/cma.j.issn.1007-3418.2012.03.019 [doi]
AB  - OBJECTIVE: To investigate the effects of the histone deacetylase inhibitor, 
      MS-275, on the immune molecule content and categories in hepatocarcinoma 
      exosomes. METHODS: Exosomes were isolated from the human hepatocarcinoma cell 
      lines, HepG2 and Hep3b, and purified by a combination technique of 
      ultrafiltration centrifugation and sucrose gradient ultracentrifugation. The 
      expressions of heat shock protein (HSP)70, human leukocyte antigen (HLA)-I, 
      HLA-DR, cluster of differentiation (CD) 80 and NY-ESO-1 on exosomes were analyzed 
      with immunoelectron microscopy and Western blotting before and after MS-275 
      treatment. Intergroup differences were statistically analyzed by the Student's 
      paired t-test. RESULTS: MS-275 treatment of both HepG2 and Hep3b cell types 
      significantly increased the numbers of exosomes, their total protein content, and 
      expression of HSP70, HLA-I and CD80 (per 100 exosomes), as compared to 
      non-treated cells (all, P less than 0.01). MS-275 was also found to induce de 
      novo expression of HLA-DR, but had no significant effect on NY-ESO-1 expression 
      (P more than 0.05). The findings from immunoelectron microscopy confirmed those 
      from Western blotting. CONCLUSION: The histone deacetylase inhibitor, MS-275, can 
      significantly alter the immune molecule content and categories in exosomes of 
      hepatocarcinoma cells. The differential expression profile may reflect an 
      anti-cancer immune response and represent molecular targets for novel 
      anti-hepatoma therapeutic or preventative strategies.
FAU - Li, Qiu-wen
AU  - Li QW
AD  - Department of Oncology, the First Affiliated Hospital, Chinese PLA General 
      Hospital, Beijing 100048, China.
FAU - Xiao, Wen-hua
AU  - Xiao WH
FAU - Sarengaowa, Gaowa
AU  - Sarengaowa G
FAU - Dong, Wei-wei
AU  - Dong WW
FAU - Zhao, Hui-xia
AU  - Zhao HX
FAU - Duan, Xin-yu
AU  - Duan XY
FAU - Zhu, Jian-hua
AU  - Zhu JH
FAU - Kang, Huan-rong
AU  - Kang HR
FAU - Fu, Yan
AU  - Fu Y
FAU - Hao, Yi-xin
AU  - Hao YX
FAU - Wang, Ru-liang
AU  - Wang RL
FAU - Song, Lin-ping
AU  - Song LP
FAU - Ye, Ming
AU  - Ye M
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Benzamides)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Pyridines)
RN  - 1ZNY4FKK9H (entinostat)
SB  - IM
MH  - Antigens, Neoplasm/immunology/metabolism
MH  - Benzamides/*pharmacology
MH  - Carcinoma, Hepatocellular/immunology/*metabolism
MH  - Exosomes/immunology/*metabolism
MH  - Hep G2 Cells
MH  - Histocompatibility Antigens Class I/immunology/metabolism
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Humans
MH  - Pyridines/*pharmacology
EDAT- 2012/04/06 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/04/06 06:00
PHST- 2012/04/06 06:00 [entrez]
PHST- 2012/04/06 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - cma.j.issn.1007-3418.2012.03 [pii]
AID - 10.3760/cma.j.issn.1007-3418.2012.03.019 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):231-5. doi: 
      10.3760/cma.j.issn.1007-3418.2012.03.019.